Background Well-differentiated grade 3 neuroendocrine tumors (NET) have recently been described as a distinct category, and randomized data regarding efficacy of therapy for these patients are scarce. In the phase 3 CABINET trial, cabozantinib improved PFS compared with placebo in patients with advanced, previously treated, progressive extra-pancreatic NET (epNET) and pancreatic NET (pNET) of all grades. Here, we evaluate if these results remain consistent in a subgroup of patients with well-differentiated G3 NET. Methods Patients with locally advanced or metastatic epNET or pNET were randomized 2:1 in independent cohorts to receive cabozantinib 60 mg daily vs placebo. We analyzed outcomes of the subset of patients with G3 NETs (Ki67>20%), combining patients in the pNET and epNET cohorts due to small sample sizes. Results 24 patients had G3 NETs, 16 randomized to cabozantinib and 8 to placebo. Primary sites included pancreas (n=12); GI tract (n=7); unknown primary (n=3); lung/ thymus (n=2). Median PFS for patients with G3 NET treated with cabozantinib was 7.9 months vs 3 months with placebo (HR=0.15,95% CI:0.04-0.57, 1-sided log-rank P=0.0034). The confirmed overall radiographic response rate was 25% (4/16) with cabozantinib vs. 0% (0/8) with placebo. Safety outcomes were consistent with published data for the trial as a whole. Conclusion Subset analysis of the CABINET trial showed improved PFS associated with cabozantinib vs placebo for G3 NETs of pancreatic and extra-pancreatic origin. Despite limited numbers, these results suggest that cabozantinib can be an effective option for patients with advanced G3 NETs.
Strosberg et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: